The Swedish pharmaceutical company, Active Biotech, has announced that the European Patent Office has granted a patent covering the use of its drug, tasquinomod, as a potential treatment for myeloma. Tasquinimod is an immunomodulatory drug with anti-cancer and anti-angiogenic properties that is currently undergoing clinical testing in prostate cancer. Promising results have been achieved with preclinical models of myeloma and the company is now seeking a partner for the continued development of tasquinimod in the clinical setting.

 

Read full article